MP30-17 TELEMEDICINE OPTIMIZES EARLY POST-OPERATIVE FOLLOW UP AFTER SYNTHETIC MID-URETHRAL SLING (MUS): A RANDOMIZED MULTI-INSTITUTIONAL CONTROL TRIAL

Le résumé fourni par la source

to evaluate the prevalence of UTIs in women newly diagnosed with GSM versus women without GSM, and 2) to assess the prevalence of UTIs in women treated with prasterone versus untreated women.METHODS: This was a retrospective cohort analysis using data from Integrated Dataverse database from Symphony Health Solutions collected between 02/2015 and 06/2019.Data was analyzed from women at least 45 years old and who have at least one year of clinical data before and after their index dates.For objective 1, index dates were defined as the first observed GSM diagnosis for the GSM cohort and as a randomly selected outpatient visit date for women without a GSM diagnosis.For objective 2, index dates were defined as the first prasterone fill date for treated women and as the initial GSM diagnosis date for untreated women.To ensure women had a balanced UTI risk profile, women treated with prasterone were matched to untreated women based on age, region, diabetes history, and number of UTI episodes in the year prior to the index date.The UTI prevalence was measured over a 1-year period after the index date.The differential prevalence was assessed using risk ratios (RR).RESULTS: The prevalence of UTIs was threefold higher (RR 3.0, 95%CI 2.97-3.04) in women diagnosed with GSM compared to matched controls (N[413,207).Women with untreated GSM (N [5,813) had an increased frequency of UTI episodes in the 12 months following the first observed GSM diagnosis (p<0.05)compared to their baseline.When compared to women with untreated GSM, women treated with prasterone had a significantly lower UTI prevalence within 12 months of the first prescription fill (RR 0.62, 95% CI (0.56 e 0.68), p<0.05).CONCLUSIONS: Women newly diagnosed with GSM have a higher rate of UTIs compared to women without GSM.Results also suggest that the use of prasterone in women diagnosed with GSM may reduce the recurrence of UTIs.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.